Background: The frequency of hepatitis C virus (HCV) infection remains high in patients with CKD and plays a detrimental role in mortality in this population, and patients undergoing maintenance dialysis are still at risk of developing HCV infection and HCV disease prevalence of anti-hepatitis C virus (HCV) patients who undergo longterm dialysis are significantly greater than those with normal kidney function. Objectives: The aim of the study was to assess outcomes (efficacy, side effects, and possible complications) of DAADs for HCV in presence of CKD. Subjects and methods: this was retrospective cohort study that was conducted at Aswan Fever Hospital and Luxor Fever Hospital for anti HCV therapy between Jan 2018 and July 2018 including 60 patients recruited from both hospitals with all stages of CKD and were receiving DAADs. Results: the results revealed that PC (%) in patients from Aswan ranged between 61-100 with mean ±S.D. 83.09±9.258 while in patients from Luxor it ranged between 66-100 with mean ±S.D. 84.95±6.764. There was no statistically significant difference between groups (P=0.458). HCV PCR in all patients from Aswan at baseline were positive while after 3 months 27 (90%) were negative and 3 (10%) were positive and after 6 months all patients were negative while in patients from Luxor they all were positive while after 3 months 28 (93.3%) were negative and 2 (6.7%) were positive and after 6 months all patients were negative. There was no statistically significant difference between groups. Conclusion: Treatment with newer DAAs is effective and safe for the treatment of HCV-infected chronic kidney disease patients.